AIM: To prevent or at least to reduce the bacterial colonization on barrier membranes during the period of membrane retention, a local sustained- release drug delivery system (SRDDS) for antibiotic was developed. The drug release behavior of such a SRDDS in vitro and in vivo was evaluated in this study. METHODS: In vitro, 6 units of SRDDS were respectively placed into PBS and the amount of daily drug release were measured by UV- spectrophotometry. In vivo, 6 units of SRDDS were respectively implanted into parietal bone defects of 6 rabbits. The concentration of drug adjacent to the defects was measured by a bioassay technique. REAULTS: In vitro, antibiotics could be steadily released from SRDDS andabout 63 % of the drug had been released by the day 28. In vivo, a unit of SRDDS could steadily release drug in effective concentration for at least 6 weeks. CONCLUSION: When the SRDDS was used underneath the barrier membranes, it seems to be able to prevent or at least reduce the bacterial colonization on the barrier membranes.%目的：为了阻止或减少口腔细菌在屏障膜放置期间定植于膜上，研制了一种抗生素的缓释给药系统(SRDDS)，并评价SRDDS在体内外的药物释放持续时间和相应浓度。方法：在体外，6个单位的SRDDS被分别置于PBS中，通过紫外分光光度法测定每日药物溶出量。在体内，在6只兔子的人工颅骨缺损中分别植入SRDDS，并通过抗生素微生物检定法测定骨缺损附近的药物浓度。结果：在体外，药物能持续稳定地从SRDDS中释放出来；至第28天，共有约63％的药物被释放。在体内，25mg/L以上的药物浓度至少能维持6周。结论：这种能移植于屏障膜下骨缺损中的SRDDS有可能阻止或减少细菌定植于屏障膜上。
展开▼
